News from Onchilles Pharma
- Clinical
Onchilles Pharma Reports First Clinical Data at SITC 2026 That N17350 Could Turn One Tumor into a Personalized Cancer Vaccine
Onchilles Pharma today announced preliminary clinical findings from OP-NEU-101, its Phase 1/2 trial of intratumoral N17350 in patients with advanced solid tumors. Initial data show no dose-limiting toxicities in three heavily pretreated patients and five non-injected lesions becoming undetectable on imaging in a patient with Merkel cell carcinoma at the starting dose.
- Clinical
Onchilles Pharma to Present OP-NEU-101 Trial in Progress at ESMO Congress 2026
Onchilles Pharma, a clinical-stage biotechnology company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced that a Trial in Progress abstract for…
- Clinical
Onchilles Pharma Doses First Patient in Phase 1/2 Clinical Trial of N17350 for Advanced Solid Tumors
N17350 is a tumor-directed therapeutic elastase designed to selectively kill cancer cells, while preserving immune cells, and to stimulate anti-tumor
- Clinical
Onchilles Pharma to Present Trial in Progress Poster at the 2026 ASCO Annual Meeting
Onchilles Pharma, a private biotech company advancing therapeutics targeting the ELANE pathway, today announced that it will present a trial in progress poster at the 2026 American Society…
- Conference
Onchilles Pharma Presents at AACR 2026 New Preclinical Data from the Systemically Delivered NEU-002 Program, Supporting Advancement Toward Development Candidate Selection
The NEU-002 program extends the ELANE pathway into systemic delivery, building on a cancer-selective mechanism that kills tumor cells while sparing immune cells and activating anti-tumor
- Conference
Onchilles Pharma to Present New Preclinical Data on Systemically Delivered NEU-002 Program at AACR 2026
Onchilles Pharma, a private biotech company advancing therapeutics targeting the ELANE pathway, today announced that new preclinical data supporting its systemically delivered NEU-002 program…
- Conference
Onchilles Pharma to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that leverage the ELANE pathway, today announced that management will present and be available…
- Clinical
Onchilles Pharma Announces IND Clearance for N17350, Advancing the First Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway into the Clinic
Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the U.S. Food and Drug Administration (FDA)…
- Science
Onchilles Pharma Publishes Landmark ELANE Pathway Study and Advances N17350 Toward the Clinic with New Financing and Leading Clinical Advisor
Peer-reviewed study in Cell Reports Medicine demonstrates that N17350 delivers selective, immune-activating tumor killing across solid tumor
- Conference
Onchilles Pharma Presents New Data at AACR 2025 Highlighting N17350, a Next-Generation Cytotoxic Therapeutic Leveraging the ELANE Pathway
First-in-class therapeutic, N17350, demonstrates potent and selective tumor killing in chemotherapy-naïve and chemotherapy-treated ovarian cancer patient-derived
- Conference
Onchilles Pharma to Present New Preclinical Data for N17350 at AACR 2025
N17350 is a next-generation cytotoxic agent designed to selectively kill cancer cells independent of anatomical locations, tumor genetics, and tumor immune status, and stimulate the immune
- Corporate
Onchilles Expands Leadership Team to Advance First-in-Class Pan-Cancer Therapeutics Targeting the ELANE Pathway into Clinical Trials
Onchilles Pharma, a private biotech company pioneering pan-cancer therapeutics that harness the ELANE pathway – a novel innate immune mechanism enabling potent and selective cancer killing…
- Conference
Onchilles Pharma Presents New Preclinical Data for the Systemically Delivered NEU-002 Program Targeting the ELANE Pathway at SITC 2024
Novel Intravenous Therapeutic Candidate Demonstrates Pan-Cancer Efficacy and Immunogenic Cell Death in Preclinical
- Conference
Onchilles Pharma Announces Presentation of Data for the NEU-002 Program at SITC 2024
Onchilles Pharma, a private biotech company developing pan-cancer therapeutics that leverage the ELANE pathway, a novel innate immune mechanism of action for potent and selective cancer…
- Press coverage
PharmaShots: Onchilles Pharma at AACR 2024: Lev Becker in a Stimulating Conversation with PharmaShots
Onchilles Pharma unveiled findings at AACR 2024 from the late-stage preclinical data of its two candidates: N17350 and N17465 (read the release
- Press coverage
SDBJ: Onchilles Pharma Shares Promising Preclinical Data; New Mechanism Discovered Could Treat Wide Range of Cancers
Jeff Clemetson of the San Diego Business Journal talked with Onchilles after the Company’s presenation at AACR 2024 of new preclinical data for N17350 and N17465 demonstrating the potential for potent and…
- Conference
Onchilles Pharma Presents at AACR 2024 New Preclinical Data for N17350 and N17465 Demonstrating the Potential for Potent and Tumor-Selective Treatment
Tumor-directed N17350 and systemically delivered N17465 are based on the breakthrough discovery of a novel innate immune mechanism of action, which activates cell death pathways specific to cancer
- Conference
Onchilles Pharma Announces Two Presentations of New Preclinical Data for N17350 and N17465 at AACR 2024
Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel innate immune mechanism of action, announced today it will unveil preclinical data on…
- Press coverage
Drug Target Review: Transforming Cancer Treatment for Greatest Impact
In this Q&A with Drug Target Review, Dr Lev Becker, Associate Professor, University of Chicago and Cofounder of Onchilles Pharma, reveals how the company is directing research into neutrophil biology to create new…
- Conference
Onchilles Pharma Presents at SITC 2023 New Preclinical Data for N17350, a Potential Pan-Cancer Therapeutic
Onchilles Pharma, a private biotech company developing cancer therapeutics that leverage a novel mechanism of action, announced the presentation of new preclinical data for N17350 at the…
- Conference
Onchilles Pharma Announces Presentation of Data for N17350 Program at SITC 2023
Onchilles Pharma, a private biotech company developing new pan-cancer therapeutics that leverage a novel mechanism of action, announced today the presentation of preclinical data for the…
- Conference
Onchilles Pharma Presents at AACR 2023 New Preclinical Data on N17350, a First-in-Class Immuno-Oncology Drug Candidate with Broad, Potent, and Direct Tumor Killing Activity
N17350 is the first drug candidate from Onchilles’ platform that is based on the breakthrough discovery of a novel mechanism of action inspired by the immunobiology of neutrophils, which activates cell death pathways…
- Conference
Onchilles Pharma Announces Presentation of Preclinical Data for N17350 at AACR 2023
The drug candidate, N17350, leverages the neutrophil elastase (ELANE) pathway, to achieve broad cancer-killing
- Corporate
Onchilles Pharma Nominates First Drug Development Candidate Targeting Neutrophil Biology for the Treatment of Cancer
The drug candidate, N17350, leverages the neutrophil elastase (ELANE) pathway, to achieve broad cancer-killing
Pioneering the use of the ELANE pathway to create the next generation of pan-cancer therapeutics.